Sun Pharmaceutical Industries Ltd. is the world’s fourth largest specialty generic pharmaceutical company. A vertically integrated business and a skilled team enables us to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Our global
presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D
centers, with investments of approximately 7% of annual revenues in R&D.
We are now poised to expand into Canada, establishing a Sun Pharma Canada Inc. affiliate in the coming months. Over the coming year, we will be launching two brands, tildrakizumab, an IL-23 for psoriasis and sonidegib, a new hedgehog inhibitor for basal cell carcinoma. Our goal is to demonstrate our commitment in Dermatology and working in close partnership with the Canadian Healthcare System and Patients.